K. Rogers, Xiaoxiao Lu, B. Emond, Z. Ding, P. Lefebvre, M. Lafeuille, Heena Mavani, Z. Qureshi, N. Ghosh
{"title":"CLL-586慢性淋巴细胞白血病患者的真实世界剂量模式和结果,有或没有一线伊鲁替尼剂量调整","authors":"K. Rogers, Xiaoxiao Lu, B. Emond, Z. Ding, P. Lefebvre, M. Lafeuille, Heena Mavani, Z. Qureshi, N. Ghosh","doi":"10.1016/s2152-2650(23)01117-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"44 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CLL-586 Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib\",\"authors\":\"K. Rogers, Xiaoxiao Lu, B. Emond, Z. Ding, P. Lefebvre, M. Lafeuille, Heena Mavani, Z. Qureshi, N. Ghosh\",\"doi\":\"10.1016/s2152-2650(23)01117-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"44 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)01117-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)01117-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CLL-586 Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib